US Drug Recall Register
Class III · Low risk Terminated Initiated Sep 25, 2018 (8 years ago)

Levofloxacin Injection in 5% Dextrose

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.

What was recalled

Levofloxacin Injection in 5% Dextrose, 5 mg/mL, packaged in a) 50 mL (NDC 36000-046-24), b) 100 mL (NDC 36000-047-24), c) 150 mL (NDC 36000-048-24) Container bags, Rx only, Manufactured for: Claris Lifesciences Inc., North Brunswick, NJ 08902; By: Claris Injectables Ltd., Gujarat, India.

Recalling firm
Baxter Healthcare Corporation
NDC code
36000-046-24
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1215-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Levofloxacin recalls

See all
Class II · Moderate risk Ongoing

Levofloxacin Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0820-2023
Class II · Moderate risk Ongoing

Levofloxacin Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0819-2023
Class II · Moderate risk Ongoing

Levofloxacin Injection 500mg/20 mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0818-2023
Class III · Low risk Terminated

Levofloxacin Tablets

Reason Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Macleods Pharma USA, INC NDC 33342-022-08 D-0162-2023